Mary Thistle - Dimension Therapeutics Chief Business Officer
Executive
Ms. Mary T. Thistle was appointed as Principal Financial and Accounting Officer, Chief Operating Officer of the Company effective July 28, 2017. Ms. Thistle joined the Company as its chief business officer in February 2015 and became the Companys chief operating officer in December 2016. From January 2014 until she joined the Company, Ms. Thistle served as senior vice president of business development at Cubist Pharmaceuticals Inc. . Ms. Thistle joined Cubist in January 2009 and served as its senior director, business development from 2009 to 2012 and then its vice president, business development from 2012 to 2013. From 1997 through 2008, Ms. Thistle served as vice president and then senior vice president at ViaCell Inc., which was acquired by PerkinElmer LAS in 2007 since 2017.
| Age | 56 |
| Tenure | 7 years |
| Professional Marks | CPA |
| Phone | 617 401-0011 |
| Web | www.dimensiontx.com |
Dimension Therapeutics Management Efficiency
Dimension Therapeutics' management efficiency ratios could be used to measure how well Dimension Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 5.78 M in liabilities with Debt to Equity (D/E) ratio of 16.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Dimension Therapeutics has a current ratio of 3.26, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Dimension Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Dimension Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Dimension Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Dimension to invest in growth at high rates of return. When we think about Dimension Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Brent Overbeek | Hawaiian Holdings | 53 | |
| Jeff Walker | Global Crossing Airlines | N/A | |
| Javier Suarez | Global Crossing Airlines | N/A | |
| Bradford Holt | Mesa Air Group | 64 | |
| Matthew CFA | HNI Corp | N/A | |
| Gregory Meunier | HNI Corp | 53 | |
| Richard Nelson | Acco Brands | N/A | |
| Jaime Pous | Volaris | 44 | |
| Lara Wilson | Global Crossing Airlines | N/A | |
| Jordi Porcel | Global Crossing Airlines | N/A | |
| Andres Pliego | Volaris | N/A | |
| Michael Roch | HNI Corp | 45 | |
| Doug Cooper | Mesa Air Group | N/A | |
| Andrea Anzures | Volaris | N/A | |
| Sheila Paine | Global Crossing Airlines | 61 | |
| Kourtney Smith | HNI Corp | 54 | |
| Christopher McGinnis | Acco Brands | N/A | |
| J Jennex | Global Crossing Airlines | N/A | |
| Paul Daniel | Acco Brands | 58 | |
| Marcy Morita | Hawaiian Holdings | N/A | |
| Michael II | Mesa Air Group | N/A | |
Management Performance
| Return On Equity | -1.0E-4 | |||
| Return On Asset | -0.0042 |
Dimension Therapeutics Leadership Team
Elected by the shareholders, the Dimension Therapeutics' board of directors comprises two types of representatives: Dimension Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dimension. The board's role is to monitor Dimension Therapeutics' management team and ensure that shareholders' interests are well served. Dimension Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dimension Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mary Thistle, Chief Business Officer | ||
| Michael Dybbs, Independent Director | ||
| Stephanie Haller, Vice President - Clinical Operations | ||
| George Migausky, Independent Director | ||
| Reed Clark, Sr. VP of Pharmaceutical Devel. | ||
| Ben Auspitz, Chairman of the Board, Co-Founder | ||
| Georges Gemayel, Independent Director | ||
| Alan Colowick, Independent Director | ||
| Rishi Gupta, Independent Chairperson of the Board | ||
| Sam Wadsworth, Chief Scientific Officer | ||
| Jean Franchi, CFO and Treasurer | ||
| Samuel Wadsworth, Chief Scientific Officer | ||
| MRCP MBBS, CEO and President and Director | ||
| Arlene Morris, Independent Director | ||
| Eric MD, Chief Medical Officer | ||
| Annalisa Jenkins, CEO, Director | ||
| John Hohneker, Director | ||
| Eric Crombez, Chief Medical Officer |
Dimension Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dimension Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.0E-4 | |||
| Return On Asset | -0.0042 | |||
| Profit Margin | (4.09) % | |||
| Operating Margin | (355.95) % | |||
| Current Valuation | 108.6 M | |||
| Shares Outstanding | 25.21 M | |||
| Shares Owned By Institutions | 71.22 % | |||
| Number Of Shares Shorted | 167.31 K | |||
| Price To Earning | (2.81) X | |||
| Price To Book | 4.13 X |
Pair Trading with Dimension Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dimension Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dimension Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Regions Financial could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Regions Financial when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Regions Financial - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Regions Financial to buy it.
The correlation of Regions Financial is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Regions Financial moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Regions Financial moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Regions Financial can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Other Consideration for investing in Dimension Stock
If you are still planning to invest in Dimension Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dimension Therapeutics' history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |